Potential limits of AAV-based gene therapy with the use of new transgenes expressing factor IX fusion proteins.

The variety of treatment for haemophilia B (HB) has recently improved with the emergence of both AAV-based gene therapy and bioengineered human factor IX (hFIX) molecules with prolonged half-life due to fusion to either albumin (Alb) or immunoglobulin Fc fragment (Fc).

Fc fusion，adeno-associated virus，albumin fusion，factor IX，gene therapy，haemoph